– USA, MA – Xilio Therapeutics, Inc., a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Sara Bonstein to its board of directors.
Sara is CFO of Insmed, Inc..
“I am very pleased to welcome Sara to our board of directors,” said Board Chairman, Dan Lynch. “With her robust experience in numerous executive leadership roles in the biotech industry, Sara brings significant experience in finance, corporate strategy and business operations, which will be invaluable as we advance our programs and transition to a clinical-stage company. Her wealth of experience complements our board, and we look forward to benefiting from her insight.”
About
Ms. Bonstein joins the Xilio board of directors with approximately 20 years of experience in the life sciences industry. Ms. Bonstein has served as chief financial officer of Insmed since January 2020. Before joining Insmed, she served as chief financial officer and chief operating officer of OncoSec Medical Incorporated from May 2018 to January 2020 and as the chief financial officer, treasurer, and executive vice president at Advaxis, Inc. from February 2014 to April 2018. In these roles, she led multiple capital markets and licensing transactions, established strong financial controls, streamlined business operations, and was responsible for the overall leadership and management of operations, including corporate finance, investor relations, and business development. Before Advaxis, Ms. Bonstein served in various finance roles of increasing responsibility at Eli Lilly & Company (Eli Lilly), ImClone Systems Incorporated, and Johnson & Johnson Inc., including as a Six Sigma Champion and Black Belt, a program implemented at Eli Lilly to enable more efficient financial growth while increasing customer satisfaction. Ms. Bonstein has served as a member of the board of directors of scPharmaceuticals Inc. since July 2020.
“The significant progress Xilio has made in the first half of this year is impressive, with encouraging preclinical data across several cytokine and antibody programs and FDA clearance of the company’s first Investigational New Drug application,” said Sara Bonstein. “I am thrilled to join Xilio’s board of directors at this exciting time for the company, and I look forward to partnering with its board and experienced management team to help advance Xilio’s pipeline of novel, tumor-selective product candidates.”
Sara holds a B.S. in finance from The College of New Jersey and an MBA from Rider University.
About Xilio Therapeutics
Xilio Therapeutics is a privately-held biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effect, resulting in the potential to achieve the enhanced anti-tumor activity. Xilio is building a pipeline of wholly-owned, tumor-selective, GPS-enabled cytokine, and checkpoint inhibitor product candidates, including XTX202, a tumor-selective IL-2; XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody; XTX301, a tumor-selective IL-12; and XTX401, a tumor-selective IL-15.
For more information: https://xiliotx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
